Functional gamma secretase inhibitors [FGSIs] can block the cleavage of several transmembrane proteins including amyloid precursor protein [APP], and the cell fate were increased in FGSI treated rats. The mouse adipsin proximal promoter contains a putative binding site for the Notch induced transcriptional regulator Hes-1, which we demonstrate is able to bind Hes-1. Additional studies in 3T3-L1 preadipocytes demonstrate that this FGSI inhibits Hes-1 expression while upregulating adipsin expression. Over-expression of Hes-1 was able to downregulate adipsin expression and block pre-adipocyte differentiation. We propose that adipsin is a Hes-1 regulated gene that is de-repressed during FGSI mediated disruption of Notch/ Hes-1 signaling.
INTRODUCTION
The small intestine can be a site of injury associated with drug treatment (1) (2) (3) . Tissue [enterocyte] fate (9) . Expression of Hes-1 is known to be regulated by Notch-1, a cell surface protein that mediates cell-fate determination by a lateral inhibition mechanism (10, 11) . When Notch-1 binds ligand (Delta, Serrate, Jagged) (12, 13) on the surface of an adjacent cell, it stimulates a cleavage of the protein within the plasma membrane by an aspartyl protease, similar or identical to the γ-secretase activity implicated in Alzheimers Disease pathogenesis (14) . Cleavage of Notch-1 releases the Notch intracellular domain
[NICD] which translocates to the nucleus, and associates with the transcriptional activator protein RBP-Jk [CSL/CBF/Su(H)/Lag-1] to stimulate the expression of target genes, most notably Hes-1 (13, 15) . Notch-1 signaling disruption (16) and Hes-1 knockout studies (17) have shown that Hes-1 plays a critical role in the differentiation processes of the gastrointestinal tract. Hes-1 transactivation is mediated by Notch processing and disruption of this processing by inhibitors of Notch-1 intra-membrane Adipsin: a biomarker of a FGSI gastrointestinal toxicity.
cleavage (18) might be expected to mirror differentiation effects seen in Hes-1 knockout studies.
Recently, γ-secretase inhibitors have been developed in an attempt to block the production of amyloid beta peptides and subsequent plaque formation in Alzheimers Disease patients (19) . Many γ-secretase inhibitors have also been shown to inhibit Notch processing (20, 21) . Given that the potential patient population for treatment of Alzheimer's Disease is elderly, the profound affects of Notch disruption seen in embryonic and fetal development may not be of concern. However, it is now known that Notch signaling plays an important role in the ongoing differentiation processes of the immune system and the gastrointestinal tract (17, 22, 23) . As a result, it may be necessary to separate γ-secretase activity on APP from Notch processing activity in order to achieve an adequate safety margin for clinical development of a FGSI therapeutic agent for Alzheimer's Disease. Achieving such a margin may be possible, as processing of these two proteins may require similar, yet independent proteolytic activities (24).
Here we report that treatment of Fisher 344 rats with high doses of an experimental γ-secretase inhibitor produced gastrointestinal changes similar to those described in Hes-1 knockout mice, including increased number of goblet cells, and elevated mRNA levels for a number of enteroendocrine specific gene products (17) . Through gene expression analysis, we have shown that the presumed adipocyte specific protein, adipsin, had Adipsin: a biomarker of a FGSI gastrointestinal toxicity.
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by guest on http://www.jbc.org/ Downloaded from similarly elevated mRNA levels and is a potential marker for Notch/Hes1 signaling disruption effects in the gastrointestinal tract of rats. Levels of this secreted protein were found to be dramatically upregulated in the intestinal contents and feces of FGSI treated rats, and could be monitored non-invasively. Immunohistochemical labeling revealed that adipsin was produced by cells present in the crypt region of the intestinal epithelium and that adipsin labeling was greater in FGSI treated rats. We also provide mechanistic evidence for adipsin gastrointestinal expression by showing that adipsin expression can be repressed by Hes-1, and reduction of Hes-1 levels by an experimental γ-secretase inhibitor released Hes-1 repression of adipsin, thus allowing for its transcriptional upregulation.
EXPERIMENTAL PROCEDURES
In vivo rat studies The experimental functional gamma secretase inhibitor Compound Adipsin: a biomarker of a FGSI gastrointestinal toxicity.
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by guest on http://www.jbc.org/ Downloaded from X ( Fig. 1A) was synthesized as described in patent application wo98/28268. Two temporal studies were conducted in Fisher 344 rats given vehicle alone (1% carboxy methyl cellulose, 0.25% polysorbate 80) or Compound X daily by oral gavage. All dose groups contained three rats per group. In the first study, doses of 10 mg/kg Compound X were administered daily for four days, two days, and one day with necropsy occurring 24 hours post last dose with additional groups terminated after four hours and two hours of treatment. In a second study, for analysis of adipsin levels in plasma and feces, rats were treated daily with 20 mg/kg Compound X for three or four days, respectively. At necropsy, sections of ileum from treated and control rats were removed for gross morphological examination, histological analysis, and RNA isolation. The doses of 10 mg/ml and 20 mg/ml of Compound X was sufficient to produce severe gastrointestinal toxicities in rats after four daily doses and significantly exceeded the levels needed for pharmacological activity in vivo, which is defined as a statistically significant reduction in brain Aβ peptide levels in young PDAPP mice. This pharmacological activity was observed within 3 hours of oral administration of 1-3 mg/kg of compound X (data not shown).
Microarray analysis Total RNA was isolated from ~100 mg rat ileum tissue, which had previously been collected and stored in RNAlater" (Ambion) by homogenization using cultures, cells were grown to confluence and maintained for 24 hours, followed by a 24 hour incubation with a cocktail containing 500 nM dexamethasone (Sigma), 500 ¼M 3-isobutyl -1-methylxanthine (Sigma) and 1.7 ¼M bovine insulin (Invitrogen). Media was then replaced with DMEM+10% FBS supplemented with 1.7 ¼M bovine insulin. Cells were maintained in this media with media replacement every 48 hours for up to ten days.
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The FGSI Compound X was prepared as a 1000x stock in DMSO and diluted in DMEM supplemented with 10% FBS prior to addition to cells.
Antipeptide antibody generation and immunoblotting -The protein sequences of rat, mouse, human, and pig adipsin were compared using multiple alignment software tools [ Clustal W] and surface probability and antigenicity programs [LaserGene®] . Regions having appropriate antigenicity profiles and corresponding to rat specific, human specific, and cross-species conserved epitopes were used to design peptides for the production of anti-peptide antibodies in rabbit. Resulting antisera were titered and affinity purified. MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM, Tris-HCl (pH 7.5), 5 mg/ml poly(dI-dC), and 5 ug protein. Binding reactions were run on a 6% DNA retardation gel (Invitrogen) until the dye front migrated 75% of the length of the gel. The dried gel was exposed to a phospho-screen for four to16 hours and the image was acquired using a Storm ® Phosphorimager (Molecular Dynamics).
Transfections -3T3-L1 cells were grown to 80% confluence. Cells were transfected with pHes-1 or pLacZ plasmids using Lipofectamine 2000 © (Invitrogen), and the media Adipsin: a biomarker of a FGSI gastrointestinal toxicity. was replaced after overnight incubation. Transfection efficiencies were determined by staining cells for beta-galactosidase activity (β-Gal staining kit, Invitrogen). After an additional 24 hrs, cells were treated with induction media as described above and incubated for 48 hrs. Cells were photographed to record morphology, and RNA was isolated for quantitative PCR as previously described. Figure 1A ) is an experimental FGSI synthesized for the purpose of blocking Aβ peptide formation. The compound is structurally similar to one previously described as Compound 6, Compound E (21, 25) and has a similar IC50, which is in the high picomolar to low nanomolar range for ABeta lowering in the APP transfected SKNMC or SH-SY5Y cell in vitro efficacy model . Treatment of Fisher 344 rats with Compound X at 10 mg/kg, a dose which is in excess of that needed for pharmacological activity (see experimental methods; in vivo rat studies) for four days produced a gastrointestinal toxicity characterized by an increase in gastrointestinal weight, distended small and large intestines, and the presence of a gelatinous material that we termed mucoid enteropathy ( Figure 1B ). Histologic Adipsin: a biomarker of a FGSI gastrointestinal toxicity. examination of ileum from Compound X treated rats revealed a profound increase in the number of goblet cells lining intestinal villi compared to vehicle treated rats ( Figure 1C and D). This increase in goblet cell number coincided with a reduction in the number of absorptive enterocytes in the villus epithelium.
RESULTS

A functional γ-secretase inhibitor produces morphological changes in the gastrointestinal tract of rats Compound X (
Gene Expression results -RNA isolated from ileum of treated rats at various times was used to generate hybridization samples that were analyzed using Affymetrix GeneChip® rat genomic RGU34A microarrays. Transcripts previously shown to be up- figure 5B. The difference in mobility of adipsin from gut contents compared to plasma may be due to differences in glycosylation levels in adipose tissue verses intestinal tissues, or partial degradation of the protein in the intestinal lumen (29) . The potential use of adipsin as a marker for compound related gastrointestinal toxicity would be greatly enhanced if it could be detected in feces instead of gastrointestinal contents, as feces can be monitored non-invasively. Therefore, rats were treated with 20 mg/kg Compound X for three days and fecal pellets were collected at 12 hour intervals. Western blot analysis revealed that considerable adipsin immunoreactive material was present in the feces of the treated rats compared to control rat feces ( Figure 5B ). Adipsin immunoreactivity in feces of treated rats was detected prior to clinical signs of gastrointestinal stress, which is exhibited by deterioration in overall general condition and stool consistency appearing after several additional days of treatment at the doses administered (data not shown). The fecal adipsin levels correlated with the levels of adipsin seen in the gastrointestinal contents (representative vehicle and compound treated rats shown in figure 5B ). To verify that the increased adipsin protein levels seen in the feces of treated rats was being produced by cells of the ileum and not a result of contaminating blood in the stool, we performed western blots with an anti-plasma albumin antibody and demonstrated that there was no difference in albumin levels found in treated and control animal feces (data not shown).
Adipsin: a biomarker of a FGSI gastrointestinal toxicity. Immunohistochemistry Results -To identify the cell type responsible for producing adipsin mRNA and protein in the rat ileum, immunohistochemical analysis was performed on sections of ileum from treated and control rats using an anti-peptide antibody generated against a conserved epitope of adipsin. Specific labeling for adipsin was present predominantly in cells in the crypt region of control and treated ileum sections, with considerably more labeling in ileum sections from Compound X treated rats. Labeled sections from a representative control and treated animal are shown in figure 6 . The specific cell type in the crypt that was positive for adipsin labeling was not clearly discernable other than that it was of a type found mostly in the base of the crypt.
.
Hes-1 can bind to sites in the adipsin proximal promoter region-Changes in Hes1
and adipsin transcript levels were inversely correlated both in vivo and in vitro ( where adipsin is normally expressed at high levels (26) . Over-expression of Hes-1 was able to dramatically block the normal up-regulation of adipsin expression seen during the differentiation of 3T3-L1 cells ( Figure 8B ) and was also able to block, to a large degree, the phenotypic changes associated with differentiation of 3T3-L1 pre-adipocytes to adipocytes ( Figure 8A ). These data imply not only a direct role for Hes-1 in repressing adipsin expression, but also a possible role for Notch-1 signaling in controlling adipocyte Adipsin: a biomarker of a FGSI gastrointestinal toxicity. 
Adipsin expression is induced in the intestinal epithelium -Although adipsin is
generally thought to be an adipocyte specific gene (32), there is evidence that it is expressed in other tissues at low to moderate levels. Adipsin expression has been reported in monocyte/macrophages, muscle, sciatic nerve, endometrium, and intestine (32, 33, 34, 36) . We have also observed low levels of adipsin in a number of tissues by RT-PCR [data not shown]. In some cases adipsin expression could be explained by isolated adipocytes present in the tissue, but in other cases, expression levels are too high to be accounted for by adipocyte contamination. We have detected adipsin transcripts in small numbers of non-adipocyte intestinal cells captured by laser capture microdissection Adipsin: a biomarker of a FGSI gastrointestinal toxicity.
(data not shown). Furthermore, low levels of adipsin were seen in the rat intestinal epithelial cell line, IEC-6, as well as the human colon adenocarcinoma cell line, Caco-2, which can be further induced by treatment of these cells with Compound X (Figure 3) .
With regard to localization of the cell type responsible for adipsin production in the ileum in vivo, immunohistochemical analysis revealed that adipsin protein is primarily present in cells of the crypt region of the ileal mucosa, and that labeling for adipsin in these cells was increased in tissue sections from Compound X treated rats (Figure 6 ). In addition, considerably greater levels of adipsin immunoreactive material was detected in gastrointestinal lumen contents and feces of Compound X treated rats compared to control rats ( Figure 5B ). Taken together, this data supports an intestinal cell source for adipsin mRNA and protein detected in the ileum tissue and gastrointestinal contents of FGSI treated rats.
Adipsin expression can be regulated by Hes-1-It is possible that adipsin expression
is normally repressed in most cell types other than mature adipocytes, and that this repression is at least partially mediated by Hes-1. We have identified the presence of a Hes-1 binding site [N-Box](11) in the mouse adipsin proximal promoter region and have shown that Hes-1 can bind to an oligonucleotide containing this site in a gel shift assay ( Figures.7B&C) . This region of the mouse adipsin proximal promoter has previously been shown to have a negative regulatory role (35) . We also have shown that overAdipsin: a biomarker of a FGSI gastrointestinal toxicity. Figure 8B ) Over-expressed Hes-1 was also able to partially block the induced differentiation of 3T3-L1 pre-adipocytes to the adipocyte phenotype ( Figure 8A ). These data suggest that Hes-1 may play a role in maintaining the pre-adipocyte fibroblast phenotype in stem cells that will later differentiate into adipocytes. This is consistent with the proposed role of Notch and Hes1 in cell fate determination (27) . The Hes-1 repressor generated from Notch signaling blocks the expression of a number of genes that would specify a particular cell fate choice, maintaining the cell in the "ground" state ( Figure 9 ). Adipsin is a gene whose expression is characteristic of mature adipocytes and is not normally expressed in the ground-state fibroblast-like 3T3-L1 pre-adipocyte (26, 36) Drosophila Atonal gene (9, 37, 38) . The proximal promoter region of the adipsin gene contains several E box, bHLH factor binding sites (Figure 7, A) where a bHLH transcription factor such as Math1 might bind and stimulate transcription (11) . Hes1 may block the binding of bHLH transcriptional activators to the adipsin promoter either directly or inhibit the action of the bHLH transactivator once bound to the promoter sequence (11) . In examining gene expression data from ileum tissue of Compound X treated rats, it was observed that expression of the gene for adipsin showed a similar pattern to those gene products representative of the secretory cell types in the ileum that would be increased when Hes-1 action is inhibited (17) . 
